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Abstract
Different clinical studies have demonstrated that fish oil, rich in the very‐long‐chain 
ω‐3 polyunsaturated fatty acids (PUFAs), has immunomodulatory effects, suppressing 
the production of pro‐inflammatory cytokines in diverse groups of critically ill patients. 
Moreover, such compounds have been found to attenuate the inflammatory response 
within 2–3 days upon parenteral administration. Recent experimental data suggest that 
activation of the cholinergic anti‐inflammatory pathway constitutes a novel mechanism 
of such immune‐regulatory effects. Since enhanced vagal tone has been associated with 
decreased cytokine secretion, novel monitoring tools of its activity at the bedside are 
needed, in order to evaluate nutritional manipulation of inflammatory response in the 
critically ill. The present chapter provides an overview of the mechanisms of action 
through which ω‐3 PUFA modulates immune response in critically ill patients suffer‐
ing from sepsis and septic shock. Furthermore, it summarizes the current evidence 
regarding clinical effects from administration of fish oil rich in ω‐3 PUFAs in septic 
patients. Finally, it presents data that suggest the existence of a continuous interrelation 
between immune status and autonomic nervous system during systemic inflammation 
and proposes novel tools of autonomic nervous system monitoring at the bedside, in 
order to assess pharmacological manipulation of immune response by ω‐3 PUFAs in 
acute illness.
Keywords: ω‐3 fatty acids, lipid emulsions, sepsis, heart rate variability, enteral, 
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1. Introduction
Acute systemic inflammation is the host response to various insults, such as infection, trauma, 
hemorrhage, etc., and is mediated by the release in circulation of different cytokines, such 
as tumor necrosis factor alpha (TNF‐α) and interleukin‐1 (IL‐1), IL‐4, IL‐6, or IL‐10 [1, 2]. 
Such mediators possess both pro‐ and anti‐inflammatory properties. Furthermore, they are 
capable to activate the hypothalamo‐pituitary‐adrenal (HPA) axis and both the sympathetic 
and parasympathetic divisions of the autonomic nervous system (ANS), which subsequently 
may affect the immune response [1].
However, safety mechanisms do sometimes fail, leading to a new continuum of disease—sepsis, 
septic shock, and multiple organ dysfunction syndrome (MODS). In this respect, patients 
develop nutrient deficiencies, which are associated with an increased risk of developing 
infections, organ failure, and death [3]. Consequently, artificial nutrition via the enteral or 
parenteral route is considered as an integral part of standard care. Recently, the concept of 
pharmaconutrition has emerged as an alternative approach, considering nutrition an active 
therapy rather than an adjunctive care [4]. Thus, specific nutrients have been designed to 
modulate the host immune response and suppress systemic inflammation. Moreover, lipid 
components of parenteral nutrition have been found to provide powerful bioactive molecules 
that may act to reduce inflammatory responses [5].
Different clinical trials have shown that fatty acids from fish oil can be considered as powerful 
disease‐modifying nutrients in patients with acute lung injury and sepsis [6, 7]. Particularly, 
feeding with fish oil rich in the very‐long‐chain, ω‐3 polyunsaturated fatty acids (PUFAs), 
eicosapentaenoic acid (EPA), and docasahexaenoic acid (DHA) has been found to attenu‐
ate the production of different cytokines, chemokines, and other effectors of innate immune 
response [8]. In addition, the recent discovery of resolvins generated by EPA and DHA has 
shed more light on resolution of inflammation, as a possible mechanism of the anti‐inflam‐
matory actions of ω‐3 PUFAs during systemic inflammation [9]. However, oral administra‐
tion of these compounds is required for several weeks to affect metabolic and inflammatory 
pathways in humans. Nevertheless, it has been recently demonstrated that intravenous 
administration of fat emulsions rich in ω‐3 PUFAs can lead to their rapid incorporation into 
phospholipids of different cells, such as platelets or monocytes, within the first 2 days of 
feeding, reducing serum pro‐inflammatory cytokines over the next 7–8 days [10–12]. This 
may affect membrane fluidity, ion channel opening, or different signal pathways, leading 
to decreased production of TNF‐α and IL‐6 [8, 10]. The bypass of the intestinal process of 
absorption that is significantly delayed during critical illness could be another reason for 
such immediate effects.
2. Anti‐inflammatory mechanisms of ω‐3 PUFA
There are two types of naturally occurring essential fatty acids (EFAs) which cannot be syn‐
thesized in the body and need to be obtained in our diet, the ω‐6 series derived from lin‐
oleic acid (LA) and the ω‐3 series derived from α‐linolenic acid (ALA). Both the ω‐6 and ω‐3 
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series are  metabolized by the same set of enzymes to their responsive long‐chain metabolites. 
In general, the term EFA includes all unsaturated fatty acids. In this respect, all EFAs are 
PUFAs, but all PUFAs are not EFAs [13]. The major metabolic pathways of ω‐3 include (1) 
 incorporation into triglycerides that are found in circulating lipoproteins; (2) incorporation 
into phospholipids of either circulating lipoproteins as well or part of cellular membranes; (3) 
be circulated as free (nonesterified) fatty acids (FFAs) in the plasma, mostly bound in albumin; 
and (4) undergo oxidation generating substrates for ATP synthesis. ω‐3 PUFAs incorporated 
in membrane phospholipids are capable to affect membrane fluidity and membrane‐associ‐
ated protein function. Furthermore, they can be cleaved by different phospholipases, giving 
rise to FFAs that subsequently are further oxidized to form various metabolites that are called 
eicosanoids (such as prostaglandins and leukotrienes) [8, 13]. These eicosanoids derived from 
EPA through different cyclo‐ and lipo‐ oxygenases are generally considered less pro‐inflam‐
matory in relation with their counterparts derived from the very‐long‐chain ω‐6 PUFA, such 
as arachidonic acid (AA). The major PUFA‐derived mediators are lipoxins, resolvins, and pro‐
tectins which are highly active and are involved in different physiological and pathophysi‐
ological processes. In this respect, experimental studies have shown that protectin D1 (PD1) 
reduces inflammatory infiltration, enhances phagocytosis of apoptotic neutrophils by mac‐
rophages, and, finally, increases macrophage migration to sites of antigen presentation. As a 
result, these metabolites seem to both inhibit the initiation of an overwhelmed inflammatory 
response and accelerate at the same time its resolution [8, 13].
The ω‐3 PUFA can also inhibit the activity of nuclear factor kB (NF‐kB), which is consid‐
ered a pivotal pro‐inflammatory transcription factor and induces the expression of many 
pro‐inflammatory genes, mediating through the production of different cytokines, the innate 
immune response [8, 9].
3. ω‐3 PUFA, the autonomic nervous system, and heart rate variability
Different experimental studies have confirmed that there is a continuous cross talk between 
the brain and the immune response to different inflammatory insults during both an acute 
and chronic inflammation. In this respect, it has been postulated that the brain may coordi‐
nate and affect at the same time the immune response. The first mechanism is based on the 
activation of vagus nerve afferent fibers, which convey the information that an inflammatory 
response takes place, through different mediators, such as cytokines [14–16].
Cytokines can activate visceral vagus afferent fibers which terminate within the dorsal vagal 
complex (DVC) of the medulla oblongata. The nucleus tractus solitarius (NTS) and the dorsal 
motor nucleus (DMN) of the vagus are part of DVC and give projections to hypothalamic 
paraventricular nucleus (PVN) that is responsible for the synthesis and release of corticotro‐
pin‐releasing hormone (CRH), with subsequent production of adrenocorticotropin hormone 
(ACTH) from the anterior pituitary. ACTH is the main inducer of the synthesis of immu‐
nosuppressive glucocorticoids from the adrenal cortex. DMN that is connected with NTS is 
believed to constitute the main site of origin of preganglionic vagus efferent fibers. NTS is also 
connected to rostral ventrolateral medulla (RVLM), which increases noradrenergic pregan‐
glionic neurons’ depolarization in the spinal cord [17]. In conclusion, the brain may alter the 
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immune response through the activation of both the sympathetic (SNS) and parasympathetic 
nervous systems (PNS), as well as the activation of the HPA axis. In this respect, the SNS may 
induce local inflammatory response through α2‐subtype adrenoreceptor stimulation by nor‐epinephrine (NE), in the early stage of inflammation. Nevertheless, stimulation of β2‐subtype adrenoreceptor‐cAMP‐protein kinase A pathway can also reduce pro‐inflammatory cytokine 
production [18–20], suggesting that SNS activation can both protect the organism from the 
detrimental effects of pro‐inflammatory cytokines and increase at same time local inflamma‐
tory response [21, 22].
Apart from the SNS, a link between the PNS of the ANS and immunoregulatory processes has 
been suggested. Thus, acetylcholine is capable to decrease TNF‐α production from human 
macrophage cultures and immune cells located in the spleen upon stimulation with endo‐
toxin, leading to its reduced release into the circulation. This effect is mediated by the specific 
α7‐subunit of the nicotinic acetylcholine receptor [23–25]. Acetylcholine is also effective in 
suppressing other pro‐inflammatory cytokines such as IL‐1β, IL‐6, and high mobility group 
box 1 (HMGB1) [26].
A novel anti‐inflammatory mechanism of lipid‐diet immunosuppressive effects has been 
recently described by Luyer and colleagues [27]. They demonstrated that high‐fat enteral 
nutrition was able to lead to attenuation of systemic inflammation in rats subjected to hemor‐
rhagic shock, through stimulation of cholecystokinin (CCK) receptors and subsequent activa‐
tion of the cholinergic anti‐inflammatory pathway.
In this respect, Tracey has suggested that for the development of new monitoring tools of 
the ω‐3 PUFA effects upon the cholinergic pathway in the clinic, new surrogate markers are 
needed [28], such as heart rate variability (HRV) analysis that is the variability of R‐R series 
in the electrocardiogram (ECG). HRV reflects both sympathetic and parasympathetic inputs 
upon the heart and can be estimated via frequency domain methods, which calculate the dif‐
ferent frequency components of a heart rate signal through a fast Fourier transformation (FFT) 
of an R‐R time series [29]. The method displays in a plot at least three peaks—fast periodicities 
[high frequency (HF), 0.15–0.4 Hz] which are largely due to the influence of vagal tone—and 
has the largest impact on HRV. Recently, it has been found that central muscarinic cholinergic 
stimulation (usually in the context of balancing cytokine production) is also accompanied 
by activation of the HF component of HRV and an instantaneous increase in total variabil‐
ity [30]. Low‐frequency periodicities (LF, 0.04–0.15 Hz) are produced by baroreflex feedback 
loops, affected mostly by sympathetic modulation of the heart, and very low frequency (VLF) 
periodicities (less than 0.04 Hz) are related to vasomotor activity. The LF/HF ratio has been 
considered as a surrogate marker of sympathovagal balance [29, 31].
Studying physiological signals of critically ill patients can easily identify “hidden” informa‐
tion, which can estimate variability and information content (entropy) as a measure of com‐
plexity, within time series [32]. It has been suggested that such measures are significantly 
altered during critical illness and may predict different outcomes of interest, such as the 
onset of septic shock and late organ dysfunction [33]. In addition, implementation of variabil‐
ity analysis of physiological signals at the bedside might give rise to new markers of disease. 
Such “physiomarkers” are generally considered more appropriate for better and more accu‐
rate early warning signs for patients, since they can be easily measured at the bedside. On the 
contrary, it has been repeatedly demonstrated that various “biomarkers” such as cytokines 
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exhibit marked interdependence, pleiotropy (multiple effects), and redundancy (multiple 
cytokines with the same effect). At the same time, their plasma concentrations fluctuate from 
day to day and correlate poorly with classic physiologic variables in septic patients [33, 34].
Both LF and HF frequency components and overall HRV are significantly reduced in septic 
patients, whereas the degree of attenuation has been found to be prognostic of survival [22, 
35]. The reduction in instantaneous HRV has been associated with an overproduction of cyto‐
kines [36], whereas pharmacological stimulation of the efferent vagus nerve has been found 
to increase the HF component of HRV and inhibit at the same time TNF‐α secretion in septic 
animals [37]. Many studies have shown that oral supplementation of ω‐3 PUFAs increases 
instantaneous HRV, reduces LF/HF ratio, and confers protection against ischemia‐induced 
ventricular tachycardia and sudden cardiac death [38, 39]. In this respect, Christensen and 
colleagues [39] demonstrated that fish oil feeding can induce an incorporation of DHA into 
the membranes of granulocytes that is associated with a dose‐response increase in HRV and 
may protect against serious ventricular arrhythmias. In a recent study [40], the intravenous 
administration of fish oil with ω‐3 PUFAs, before endotoxin injection in healthy volunteers, 
was able to blunt fever response and sympathetic stimulation and enhance vagal tone, esti‐
mated with HRV analysis. This reduction was associated with a significant decrease in plasma 
norepinephrine and adrenocorticotropin hormone (ACTH) levels. Such effects of fish oil 
reflect an enhanced efferent vagal activity via a central‐acting mechanism due to a possible 
suppression of pro‐inflammatory cytokines, which have been found to inhibit central vagal 
neurons [8, 41].
However, different interventional studies on ω‐3 PUFAs and HRV in patients with heart dis‐
ease have found inconsistent results, with only 8 out of the 20 trials published so far, support‐
ing a beneficial effect on HRV [42]. Thus, Mozaffarian et al. [43] found that individuals with 
the highest fish consumption (≥5 meals/week) exhibited 1.5 ms greater HRV than those with 
the lowest fish consumption. Moreover, this modest reduction in HRV was associated with 
only a 1.1% reduction in the relative risk for sudden cardiac death. As we have stated else‐
where [44], “reasons for such inconsistency might include heterogeneous populations, lim‐
ited sample sizes or different study protocols with variable administered doses of ω‐3 PUFA 
and length of intervention.” Furthermore, “different methods of measurement of HRV with 
variable time of recordings could be an additional confounder” [42–44]. Another potential 
limitation of such measures could be associated with the fact that a reduction in pacemaker 
funny current rather than an alteration in autonomic neural output was found to be respon‐
sible for heart rate reduction and increase in HRV in an animal study with administration of 
ω‐3 PUFAs [45]. Nevertheless, a potential impact of autonomic tone on HRV cannot be evalu‐
ated in this study since experiments were performed in denervated hearts.
In conclusion, an association has been suggested between increased HRV and fish oil admin‐
istration in different groups of patients with cardiovascular diseases [38, 39, 42]. However, 
the possible relationship between HRV changes and inflammatory markers during fish oil 
feeding has not been studied yet, in septic patients. Thus, we think that a promising approach 
could be the assessment of the relationship between vagal activity estimated with HRV and 
inflammatory markers in septic patients, during parenteral fish oil feeding. In this case, we 
assume a beneficial effect of ω‐3 PUFAs on HRV and cytokine response, early in the course 
of disease.
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4. Clinical studies
In Europe there are currently three available lipid emulsions containing ω‐3 fish oil for IV 
administration: Omegaven (Fresenius Kabi, Germany) that is a 10% fish oil emulsion supple‐
ment; Lipoplus/Lipidem (B Braun, Germany) that contains a mixture of 50% medium‐chain 
triglycerides (MCT) and 40% soybean oil (SO) that is rich in ω‐6 PUFA, such as LA and 10% 
fish oil; and Smoflipid (Fresenius Kabi, Germany) that is a four‐oil mixture of 30% soybean oil, 
30% MCT, 25% olive oil, and 15% fish oil [13].
Numerous studies in critically ill patients have found favorable effects of ω‐3 fish oil on differ‐
ent aspects of inflammatory response. Mayer and colleagues [10] randomized 21 septic patients 
requiring parenteral nutrition to receive an IV lipid emulsion rich either in ω‐3 (Omegaven) 
or ω‐6 (Lipoven) PUFAs. They were able to show that the first group within 2 days of infu‐
sion demonstrated a rapid incorporation of ω‐3 fatty acids into mononuclear leukocyte mem‐
branes. In addition, fish oil rich in ω‐3 was found to suppress generation of pro‐inflammatory 
cytokines from mononuclear leukocytes upon ex vivo stimulation with endotoxin. Heller and 
colleagues [46] demonstrated that IV ω‐3 PUFA administration (Omegaven) in 661 surgical 
critically ill patients improved survival and reduced infection rates, antibiotic requirement, 
and length of stay in a dose‐dependent manner. Moreover, IV fish oil was found safe, confer‐
ring significant clinical benefits when administered in doses between 0.1 and 0.2 gr/Kg/day. In 
two other studies evaluating fish oil parenteral administration in surgical patients admitted to 
the Intensive Care Unit (ICU), it was found that although a short‐term (<5 days) administra‐
tion influences immune parameters, postoperative administration may further reduce length 
of stay and infectious complications in the ICU [12, 47]. In this respect Braga et al. concluded 
that ω‐3 should be given prior to surgery in order to enhance their anti‐inflammatory effects 
in the postoperative period [48].
Barbosa et al. [11] evaluated the effects of IV fish oil administration (Lipoplus) for 5 days in 25 
septic ICU patients. They found a significant decrease in IL‐6 plasma concentration, reduced 
hospital length of stay and amelioration in gas exchange during the sixth day of stay in the ICU.
In 2014, Manzanares and colleagues [49] after aggregating six randomized controlled trials 
(RCTs) evaluating the effects of parenteral fish oil on relevant clinical outcomes in a hetero‐
geneous group of critically ill patients were able to demonstrate a significant reduction in 
mortality and duration of mechanical ventilation. In 2015, the same group of researchers, 
after analyzing data from 10 RCTs involving 733 patients, was not able to find any survival 
benefit from parenteral fish oil feeding in septic patients [50]. Nevertheless, a reduction in the 
incidence of infections and a trend toward reduced duration of mechanical ventilation and 
length of stay in ICU were reported. Furthermore, intravenous fish oil feeding exhibited a 
nonsignificant trend toward reduced mortality. Since conflicting data have been originated 
from other systematic reviews and meta‐analyses [51, 52] “low sample size and heterogeneity 
of the cohorts included do not permit a final recommendation on the use of ω‐3 PUFAs as a 
pharmaconutrient strategy in septic ICU patients” [50].
The European Society for Clinical Nutrition and Metabolism (ESPEN) Guidelines on Paren teral 
Nutrition in Intensive Care has suggested that both EPA and DHA can affect cell  membranes and, 
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subsequently, reduce the intensity of inflammatory response. As a result, fish oil‐enriched lipid 
emulsions might decrease duration of hospitalization in critically ill patients [53]. Canadian 
recommendations also endorse the use of fish oil‐enriched lipid emulsions when parenteral 
nutrition is indicated [54]. Finally, the American Society for Parenteral and Enteral Nutrition 
(ASPEN) in its recently published guidelines cannot recommend fish oil parenteral feeding 
in critically ill patients at this time, due to lack of availability on the market of these products 
in the United States, despite approval by the FDA in 2013 [55]. Nevertheless, it considers as 
appropriate its future administration either in patients with septic shock who are candidates 
for parenteral nutrition due to hemodynamic compromise, such as hypotensive (mean arterial 
blood pressure < 50 mm Hg); patients for whom catecholamine agents (e.g. norepinephrine, 
epinephrine) are being initiated and patients for whom escalating doses are required to main‐
tain hemodynamic stability; or surgical postoperative patients who are not eligible for enteral 
nutrition (e.g. short bowel) [55].
Different studies have also assessed potential differences between SO and fish oil lipid IV fat 
emulsions in septic patients. In a recent systematic review of 12 RCTS including 806 patients 
by Manzanares and colleagues, no significant difference in outcome benefits was found [56]. 
In another meta‐analysis of eight RCTS involving 391 patients by Palmer et al. [52], a signifi‐
cant reduction in hospital length of stay was demonstrated by nearly 10 days in those receiv‐
ing ω‐3 fish oil in relation with either SO‐based or SO + MCT‐based lipid emulsions. However, 
no differences were seen between groups with regard to ICU length of stay, infectious compli‐
cations, and mortality. The strongest evidence in favor of fish oil PUFAs than SO‐based lipid 
emulsions comes from small observational studies [55]. In this respect, data collected from 
an International Nutritional Survey showed a significantly lower ICU length of stay, reduced 
duration of mechanical ventilation, and reduced ICU mortality in septic patients receiving 
fish oil PUFAs when compared with SO‐based lipid emulsions [57].
Another issue that has been tested in different RCTs is associated with safety and tolerability. 
Recently, a meta‐analysis of 23 trials involving 1503 patients receiving long‐term parenteral 
nutrition with IV fish oil found no evidence of any deleterious effects [58]. Consequently, 
ESPEN Guidelines on Parenteral Nutrition in Intensive Care suggests that lipids and essential 
fatty acids should be an integral part of the regimen to provide energy and should be admin‐
istered at a rate of 0.7–1.5 gr/Kg over 12–24 h [53].
Considering enteral administration of lipid emulsions rich in ω‐3 PUFAs in critically ill 
patients with sepsis and septic shock, strong evidence is still lacking. While early studies 
and meta‐analyses suggested reduced infection rates, ICU length of stay, and duration of 
mechanical ventilation, in both medical and surgical patients in a general ICU [59], Heyland 
and colleagues found a modest reduction in hospital length of stay, particularly in medical 
patients [60]. Furthermore and according to ASPEN Guidelines, current evidence does not 
support the use of enteral fish oil administration, particularly in medical ICU patients, due to 
heterogeneity of studies, variety of experimental and commercial lipid formulations, variable 
dosage of individual components, and increased costs [55]. Finally, two recent meta‐analyses 
showed that the effect of fish oil lipid emulsions on mortality in septic patients was not influ‐
enced by the route of administration (enteral vs. parenteral) [50, 61].
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5. Conclusions
Many experimental studies have confirmed that ω‐3 PUFAs possess different anti‐inflammatory 
properties. Either through effect on membrane fluidity with subsequent attenuation of cytokine 
production or through indirect activation of the cholinergic anti‐inflammatory pathway (immu‐
noreflex), fish oil lipids have demonstrated immune‐regulatory activities in different experimen‐
tal settings. As a result, different investigators have evaluated their role in different groups of 
patients exhibiting systemic inflammation, such as surgical or septic patients treated in the ICU. 
However, extreme heterogeneity in patients’ populations, route of administration, doses and 
duration of therapy, as well as commercially available products limits generalizability of results 
derived from numerous systematic reviews and meta‐analyses. Consequently and since the cur‐
rent evidence is still too weak and sparse to make recommendations about the role of fish oil in 
the treatment of the critically ill, we suggest that HRV could be adopted as end point for moni‐
toring nutritional manipulation of inflammatory response at the bedside, helping translation of 
basic science results into successful randomized controlled trials. In this case, we assume that ω‐3 
PUFAs upon parenteral administration will be rapidly incorporated into the phospholipid mem‐
branes of different immune cell types, reducing the inflammatory response and increasing HRV.
In this respect, 24 h recordings and longitudinal changes of HRV in two groups of septic 
patients with similar severity of disease and receiving parenteral nutrition with the same vol‐
ume of glucose, nitrogen, and fat but different lipid composition could be tested. In the case 
that HRV metrics predict outcomes of interest, such as lower infection rate and/or attenuated 
organ dysfunction, such a study might identify a unique value of HRV analysis as a monitor‐
ing tool of inflammatory modulation by fish oil feeding, in septic patients. Another potential 
use of HRV in artificial nutrition of septic patients as has been suggested by Tracey [62] could 
be its adoption as a physiomarker to early identify patients with reduced vagal tone. In this 
case, a susceptibility to increased inflammation can be assumed, whereas HRV metrics might 
serve as an early alarm to identify patients who might benefit from pharmacological stimula‐
tion of the cholinergic anti‐inflammatory pathway, such as ω‐3 PUFAs [62].
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